To determine whether low doses of celecoxib also increased reduction in viable cell counts of colorectal carcinoma cells with undetectable basal Cox-2 expression, we performed the same experiment on colorectal carcinoma cells HCT-116 previously shown to be Cox-2 deficient [20]. Here, PTGS2 is linked to colorectal carcinoma.